指南与共识呼吸道感染

成人及高危人群PCV20疫苗接种建议

Recommendations on PCV20 vaccine in adults and at-risk populations
RSS 订阅 · 指南共识 · 肺炎 · 2025-11-12

本文为叙述性综述,通过检索PubMed、Scopus及政府网站,汇总各国关于20价肺炎球菌结合疫苗(PCV20)在成人和高危人群中的接种建议、安全性、耐受性及成本效果。结果显示,65岁以上成人推荐单剂PCV20,既往接种PCV13或PPSV23者推荐单剂PCV20加强;未完成PCV13或PPSV23接种程序者亦推荐PCV20。多个国家已将PCV20纳入高危成人及儿童接种。

要点

  • 65岁以上成人推荐单剂PCV20,既往接种PCV13或PPSV23者推荐单剂加强。
  • 未完成PCV13或PPSV23接种程序者推荐接种PCV20。
  • 多个国家已将PCV20纳入高危成人及儿童接种。

核心结论

  • PCV20的有效性、安全性和成本效果支持其用于各年龄组包括有基础疾病者预防侵袭性和非侵袭性肺炎球菌疾病。

研究设计与样本

  • 叙述性综述,通过PubMed、Scopus和政府网站全面检索PCV20相关文献、研究及建议。

主要发现

  • 65岁以上成人推荐单剂PCV20,既往接种PCV13或PPSV23者推荐单剂PCV20加强。
  • 未完成PCV13或PPSV23接种程序者亦推荐接种PCV20。
  • 多个国家已将PCV20纳入高危成人及儿童接种。

关键数值与推荐

  • 65岁以上成人:单剂PCV20。
  • 既往接种PCV13或PPSV23者:单剂PCV20加强。
  • 未完成PCV13或PPSV23接种程序者:推荐PCV20。

临床怎么用

  • 对65岁以上成人及有基础疾病的高危人群,可依据当地建议评估接种PCV20。
  • 对既往接种PCV13或PPSV23者,可考虑单剂PCV20加强。
  • 对未完成PCV13或PPSV23接种程序者,可选用PCV20完成接种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eur Respir Rev. 2025 Nov 12;34(178):250016. doi: 10.1183/16000617.0016-2025. Print 2025 Oct. ABSTRACT INTRODUCTION: Streptococcus pneumoniae is a common cause of bacterial pneumonia, bacteraemia and meningitis in adults, especially among older adults and individuals with specific underlying medical conditions. The composition of the capsular polysaccharides distinguishes different pneumococcal serotypes and serves as the target for commercially available vaccines. The 20-valent pneumococcal conjugate vaccine (PCV20) was introduced in 2021, conferring protection to seven additional serotypes over PCV13 and five over PCV15, and, thus, providing increased coverage against common serotypes that cause invasive pneumococcal disease (IPD) and community-acquired pneumonia. The present narrative review summarises current recommendations for pneumococcal vaccination in different countries, focusing on adult and at-risk populations, safety, tolerability, and cost-effectiveness. METHODS: A comprehensive search of existing literature was conducted on PubMed, Scopus and government websites to gather relevant articles, studies and recommendations about PCV20. The information was summarised to provide an overview. RESULTS: The recommendations for adults over 65 years of age support the use of a single dose of PCV20, and a single booster of PCV20 for people who had previously received PCV13 or PPSV23. The administration of PCV20 is also recommended for those who have not completed the vaccine schedules for PCV13 or PPSV23. Several countries have recently included PCV20 in the vaccination of adults and children at higher risk of developing IPD. CONCLUSION: The efficacy, safety and cost-effectiveness of PCV20 support its use in preventing invasive and noninvasive pneumococcal disease across age groups, including those with underlying health conditions. PMID: 41224370 | PMC: PMC12606068 | DOI: 10.1183/16000617.0016-2025

来源:指南共识 · 肺炎,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 肺炎:Recommendations on PCV20 vaccine in adults and at-risk populations

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。